Key Equity Research Analysts at Barclays Capital Maintained their ‘Overweight’ rating for Shire PLC (LON:SHP) Shares Today. Their Target Price Provided Is GBX 5700.00

Share

Shire PLC (LON:SHP) Rating Reaffirmed

Barclays Capital now has a GBX 5700.00 target price on shares of Shire PLC (LON:SHP). The target price may imply a potential upside of 40.91% from the stock close price of Shire PLC (LON:SHP). This rating was revealed to clients and investors in recent note on Tuesday morning.

From a total of 10 analysts covering Shire PLC (LON:SHP) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 65% of the ratings are positive. The highest target price is GBX 96.71 while the lowest target price is GBX 81.97. The mean of all analyst targets is GBX 89.82 with a 31.76% above today’s (GBX 4089) stock price. Shire PLC was the topic of 84 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. Bernstein maintained shares on December 14 with “Outperform” rating. Credit Suisse maintained shares with “Neutral” rating and GBX 5400 target share price in a report from a November 4. J.P. Morgan maintained SHP stock in a recent report from December 4 with “Overweight” rating. Barclays Capital maintained the rating on November 3. Barclays Capital has a “Overweight” rating and a GBX 5700 price target on shares. Finally, Berenberg maintained the stock with “Buy” rating in a report issued on a November 16.

The stock closed the day at GBX 4089 during the previous session. It is down 23.93% since May 18, 2015 and is downtrending. It has underperformed by 20.25% the S&P500.

Key Equity Research Analysts at Barclays Capital Maintained their ‘Overweight’ rating for Shire PLC (LON:SHP) Shares Today. Their Target Price Provided Is GBX 5700.00

Shire plc is a biopharmaceutical company. The company has a market cap of 24.34 billion GBP. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 12.02 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.

COMMENTS: